[go: up one dir, main page]

MX2016016868A - Derivados de exendina-4 como agonistas selectivos del receptor de glucagon. - Google Patents

Derivados de exendina-4 como agonistas selectivos del receptor de glucagon.

Info

Publication number
MX2016016868A
MX2016016868A MX2016016868A MX2016016868A MX2016016868A MX 2016016868 A MX2016016868 A MX 2016016868A MX 2016016868 A MX2016016868 A MX 2016016868A MX 2016016868 A MX2016016868 A MX 2016016868A MX 2016016868 A MX2016016868 A MX 2016016868A
Authority
MX
Mexico
Prior art keywords
glucagon receptor
receptor agonists
exendin
derivatives
glucagon
Prior art date
Application number
MX2016016868A
Other languages
English (en)
Other versions
MX367348B (es
Inventor
Evers Andreas
Haack Torsten
Wagner Michael
Henkel Bernd
Stengelin Siegfried
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2016016868A publication Critical patent/MX2016016868A/es
Publication of MX367348B publication Critical patent/MX367348B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a agonistas de receptor de glucagón y a su uso médico, por ejemplo en el tratamiento de la hipoglucemia grave. Se proporcionan análogos de exendina-4, los cuales activan de manera potente y selectiva el receptor de glucagón y muestran una mayor solubilidad a un pH neutral cercano y una estabilidad química en solución mejorada comparada con glucagón natural. Los análogos tienen el aminoácido artificial 4-tiazolilalanina en la posición 1. Esto resulta en mayor selectividad hacia el receptor de glucagón versus el receptor GLP1 cuando los compuestos idénticos son comparados unos con otros difiriendo solamente en la posición 1 (Tza en posición 1 en lugar de His). La presente invención proporciona agonistas de receptor de glucagón altamente selectivos.
MX2016016868A 2014-06-18 2015-06-17 Derivados de exendina-4 como agonistas selectivos del receptor de glucagon. MX367348B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14305935 2014-06-18
PCT/EP2015/063607 WO2015193381A1 (en) 2014-06-18 2015-06-17 Exendin-4 derivatives as selective glucagon receptor agonists

Publications (2)

Publication Number Publication Date
MX2016016868A true MX2016016868A (es) 2017-03-27
MX367348B MX367348B (es) 2019-08-15

Family

ID=50981447

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016868A MX367348B (es) 2014-06-18 2015-06-17 Derivados de exendina-4 como agonistas selectivos del receptor de glucagon.

Country Status (26)

Country Link
US (1) US9932381B2 (es)
EP (1) EP3157949B1 (es)
JP (1) JP6581606B2 (es)
KR (1) KR20170018433A (es)
CN (1) CN106715466B (es)
AR (1) AR100888A1 (es)
AU (1) AU2015276203B2 (es)
BR (1) BR112016029582A2 (es)
CA (1) CA2951077A1 (es)
CY (1) CY1121032T1 (es)
DK (1) DK3157949T3 (es)
ES (1) ES2691534T3 (es)
HR (1) HRP20181708T1 (es)
HU (1) HUE039702T2 (es)
IL (1) IL249583A0 (es)
LT (1) LT3157949T (es)
MX (1) MX367348B (es)
PL (1) PL3157949T3 (es)
PT (1) PT3157949T (es)
RU (1) RU2017101377A (es)
SG (1) SG11201609478PA (es)
SI (1) SI3157949T1 (es)
TR (1) TR201815158T4 (es)
TW (1) TW201613633A (es)
UY (1) UY36179A (es)
WO (1) WO2015193381A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3456340T3 (da) 2007-01-08 2022-03-21 Univ Pennsylvania Glp-1-receptorantagonist til brug ved behandling af medfødt hyperinsulisme
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
MX2015008114A (es) 2012-12-21 2015-11-06 Sanofi Sa Derivados de exendina-4.
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US10772556B2 (en) * 2014-11-05 2020-09-15 Cláudio Afonso Ambrósio Method and system for monitoring and treating hypoglycemia
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
WO2016191395A1 (en) 2015-05-22 2016-12-01 The Bot Of The Leland Stanford Junior University Treatment of post-bariatric hypoglycemia with exendin(9-39)
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
BR112018011892A2 (pt) * 2015-12-14 2018-12-04 Sanofi agonistas seletivos do receptor de glucagon compreendendo uma porção quelante para propósitos de produção de imagem
CN113546159B (zh) * 2015-12-29 2023-09-08 派格生物医药(苏州)股份有限公司 包含glp-1受体激动剂和胰高血糖素受体激动剂的组合物及其用途
US10653753B2 (en) 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
PT3541366T (pt) 2016-11-21 2025-03-14 Univ Leland Stanford Junior Formulações tamponadas de exendina (9‑39)
AU2019263490A1 (en) * 2018-05-04 2020-11-26 Insulet Corporation Safety constraints for a control algorithm-based drug delivery system
WO2022131141A1 (en) 2020-12-14 2022-06-23 L'oreal Multi-phase composition comprising alpha hydroxy acid
FR3118872B1 (fr) 2021-01-15 2024-02-02 Oreal Composition multiphasique comprenant un alpha-hydroxyacide
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (419)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
NZ250844A (en) 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5641757A (en) 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
CA2262647C (en) 1996-08-08 2007-12-04 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA72181C2 (uk) 1996-08-30 2005-02-15 Ново Нордіск А/С Похідна глюкагоноподібного пептиду-1 (варіанти), фармацевтична композиція та спосіб одержання лікувального засобу (варіанти), спосіб лікування діабету (варіанти) і ожиріння
PT1629849E (pt) 1997-01-07 2013-07-09 Amylin Pharmaceuticals Llc Composições farmacêuticas que compreendem exendinas e seus agonistas
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6723530B1 (en) 1997-02-05 2004-04-20 Amylin Pharmaceuticals, Inc. Polynucleotides encoding proexendin, and methods and uses thereof
NZ502592A (en) 1997-08-08 2002-03-28 Amylin Pharmaceuticals Inc Exendin agonist peptides and their use in the treatment of type I and II diabetes
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US7220721B1 (en) 1997-11-14 2007-05-22 Amylin Pharmaceuticals, Inc. Exendin agonist peptides
NZ504256A (en) 1997-11-14 2003-01-31 Amylin Pharmaceuticals Inc Exendin 3 and 4 agonist compounds for treating diabetes
WO1999025727A2 (en) 1997-11-14 1999-05-27 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
JP4353544B2 (ja) 1998-01-09 2009-10-28 アミリン・ファーマシューティカルズ，インコーポレイテッド アミリン作動薬ペプチド用製剤
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
NZ506839A (en) 1998-03-09 2003-05-30 Zealand Pharma As Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
JP4072319B2 (ja) 1998-03-13 2008-04-09 ノヴォ ノルディスク アクティーゼルスカブ 安定化水溶性ペプチド溶液
US6998387B1 (en) 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
HUP0102193A2 (hu) 1998-06-12 2001-10-28 Bionebraska, Inc. Glukagonszerű peptid-1, mely a béta-sejtek glükózra adott válaszát glükóz toleranciában sérült személyeknél javítja
DK1105460T3 (da) 1998-08-10 2010-02-08 Us Gov Health & Human Serv Differentiering af ikke-insulinproducerende celler til insulinproducerende celler med GLP-1 eller Exendin-4 og anvendelser deraf
AU765584B2 (en) 1998-09-17 2003-09-25 Eli Lilly And Company Protein formulations
US6429197B1 (en) 1998-10-08 2002-08-06 Bionebraska, Inc. Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
US7259136B2 (en) 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
ES2249933T3 (es) 1998-12-22 2006-04-01 Eli Lilly And Company Formulacion autoestable de peptido 1 tipo glucagon.
US20030087820A1 (en) 1999-01-14 2003-05-08 Young Andrew A. Novel exendin agonist formulations and methods of administration thereof
US7399489B2 (en) 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
ES2343072T3 (es) 1999-01-14 2010-07-22 Amylin Pharmaceuticals, Inc. Exendina para la supresion del glucagon.
RU2242244C2 (ru) 1999-01-14 2004-12-20 Амилин Фармасьютикалз, Инк. Новые композиции агонистов эксендина и способы их введения
US6451974B1 (en) 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
BR0009040A (pt) 1999-03-17 2001-12-18 Novo Nordisk As Método para acilar um grupo amino de um peptìdeoou de uma proteìna, e, composto
CA2372214A1 (en) 1999-04-30 2000-11-09 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
WO2000069911A1 (en) 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting insulinotropic peptides
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6482799B1 (en) 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6344180B1 (en) 1999-06-15 2002-02-05 Bionebraska, Inc. GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US6972319B1 (en) 1999-09-28 2005-12-06 Bayer Pharmaceuticals Corporation Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
ATE275967T1 (de) 2000-01-10 2004-10-15 Amylin Pharmaceuticals Inc Verwendung von exendinen und deren agonisten zur behandlung von hypertriglyceridämie
CN1487836A (zh) 2000-03-14 2004-04-07 埃米林药品公司 胰高糖素样肽1(7-36)对胃窦幽门十二指肠能动性的影响
US20020061838A1 (en) 2000-05-17 2002-05-23 Barton Holmquist Peptide pharmaceutical formulations
CN103356996A (zh) 2000-05-19 2013-10-23 埃米林药品公司 Glp-1用于制备治疗急性冠脉综合征的药物的用途
EP1317412A1 (en) 2000-08-18 2003-06-11 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US7507714B2 (en) 2000-09-27 2009-03-24 Bayer Corporation Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use
WO2002034285A2 (en) 2000-10-20 2002-05-02 Coolidge Thomas R Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
IL155812A0 (en) 2000-12-07 2003-12-23 Lilly Co Eli Glp-1 fusion proteins
WO2002047716A2 (en) 2000-12-13 2002-06-20 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
GB2371227A (en) 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
CN1162446C (zh) 2001-05-10 2004-08-18 上海华谊生物技术有限公司 促胰岛素分泌肽衍生物
EP1542712A2 (en) 2001-06-01 2005-06-22 Eli Lilly And Company Glp-1 formulations with protracted time action
JP5562510B2 (ja) 2001-06-28 2014-07-30 ノヴォ ノルディスク アー／エス 修飾ｇｌｐ−１の安定な処方剤
IL159857A0 (en) 2001-07-16 2004-06-20 Hk Pharmaceuticals Inc Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
EP2275117B1 (en) 2001-07-31 2016-10-26 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services GLP-1, exendin-4, peptide analogs and uses thereof
JP2005508895A (ja) 2001-08-28 2005-04-07 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１および基礎インスリンの予備混合物
US7179788B2 (en) 2001-10-19 2007-02-20 Eli Lilly And Company Biphasic mixtures of GLP-1 and insulin
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
US7105489B2 (en) 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
RU2332229C2 (ru) 2002-02-20 2008-08-27 Эмисфире Текнолоджис Инк. Способ введения молекул glp-1
PT1478394E (pt) 2002-02-27 2008-10-08 Immunex Corp Composição estabilizada compreendendo tnfr - fc e arginina
EP1502102B1 (en) 2002-03-11 2009-01-14 caprotec bioanalytics GmbH Compounds and methods for analyzing the proteome
US7141240B2 (en) 2002-03-12 2006-11-28 Cedars-Sinai Medical Center Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
JP2005535569A (ja) 2002-04-04 2005-11-24 ノボ・ノルデイスク・エー／エス Ｇｌｐ−１アゴニスト及び心臓血管合併症
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
US20040037826A1 (en) 2002-06-14 2004-02-26 Michelsen Birgitte Koch Combined use of a modulator of CD3 and a GLP-1 compound
EP1515749B1 (en) 2002-06-14 2012-08-15 Novo Nordisk A/S Combined use of a modulator of cd3 and a glp-1 compound
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
DK1525219T3 (da) 2002-07-04 2009-09-07 Zealand Pharma As GLP-1 og fremgangsm der til behandling af diabetes
US20070065469A1 (en) 2002-07-09 2007-03-22 Michael Betz Liquid formulations with high concentration of human growth hormone (high) comprising glycine
MXPA05000412A (es) 2002-07-09 2005-07-22 Sandoz Ag Formulacioneks liquidas con una alta concentracion de hormona de crecimiento humana (hgh) que comprenden glicina.
AU2003257156B2 (en) 2002-08-01 2007-08-30 Mannkind Corporation Cell transport compositions and uses thereof
US20040038865A1 (en) 2002-08-01 2004-02-26 Mannkind Corporation Cell transport compositions and uses thereof
US20080260838A1 (en) 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
KR101150449B1 (ko) 2002-08-21 2012-06-01 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 8-［3-아미노-피페리딘-1-일］-크산틴, 이의 제조방법 및 이를 포함하는 약제학적 조성물
AU2003268621B2 (en) 2002-10-02 2009-01-15 Zealand Pharma A/S Stabilized exendin-4 compounds
US6969702B2 (en) 2002-11-20 2005-11-29 Neuronova Ab Compounds and methods for increasing neurogenesis
PT1583541E (pt) 2002-11-20 2011-04-06 Neuronova Ab Compostos e métodos para o aumento da neurogénese
US20050209142A1 (en) 2002-11-20 2005-09-22 Goran Bertilsson Compounds and methods for increasing neurogenesis
JP2006514035A (ja) 2002-12-17 2006-04-27 アミリン・ファーマシューティカルズ，インコーポレイテッド 心不整脈の予防および治療
US7790681B2 (en) 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
US20040209803A1 (en) 2002-12-19 2004-10-21 Alain Baron Compositions for the treatment and prevention of nephropathy
CA2843439A1 (en) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd Reversible pegylated drugs
WO2004089985A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
WO2004103390A2 (en) 2003-05-15 2004-12-02 Trustees Of Tufts College Stable analogs of peptide and polypeptide therapeutics
CN1747748B (zh) 2003-05-23 2011-01-19 尼克塔治疗公司 具有特定原子排列的聚合物衍生物
US7947261B2 (en) 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
WO2005000222A2 (en) 2003-05-30 2005-01-06 Amylin Pharmaceuticals, Inc. Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
JP2007524592A (ja) 2003-06-03 2007-08-30 ノボ・ノルデイスク・エー／エス 安定化された薬学的ペプチド組成物
ATE541582T1 (de) 2003-06-03 2012-02-15 Novo Nordisk As Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen
ATE529126T1 (de) 2003-06-03 2011-11-15 Novo Nordisk As Stabilisierte pharmazeutische peptid zusammensetzungen
EP1633390B1 (en) 2003-06-03 2012-01-18 Novo Nordisk A/S Stabilized pharmaceutical glp-1 peptide compositions
US8921311B2 (en) 2003-08-01 2014-12-30 Mannkind Corporation Method for treating hyperglycemia
EP2264065B1 (en) 2003-08-05 2017-03-08 Novo Nordisk A/S Novel insulin derivatives
KR20060106812A (ko) 2003-08-21 2006-10-12 노보 노르디스크 에이/에스 라세미화 아미노산을 포함하는 폴리펩티드의 분리
EP1663295A2 (en) 2003-09-01 2006-06-07 Novo Nordisk A/S Stable formulations of peptides
US20060247167A1 (en) 2003-09-01 2006-11-02 Novo Nordisk A/S Stable formulations of peptides
TW200522976A (en) 2003-09-19 2005-07-16 Novo Nordisk As Novel plasma protein affinity tags
US20060287221A1 (en) 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
WO2005046716A1 (en) 2003-11-13 2005-05-26 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and a insulin peptide of short time action for treatment of diabetes and bulimia
US20050106214A1 (en) 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
US20050281879A1 (en) 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
CN1882356B (zh) 2003-11-20 2015-02-25 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
EP1750752A2 (en) 2003-11-20 2007-02-14 Neuronova AB Compounds and methods for increasing neurogenesis
CN1902226A (zh) 2003-12-03 2007-01-24 诺和诺德公司 单链胰岛素
US9539337B2 (en) 2003-12-10 2017-01-10 Nektar Therapeutics Compositions comprising two different populations of polymer-active agent conjugates
US20050143303A1 (en) 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US20060210614A1 (en) 2003-12-26 2006-09-21 Nastech Pharmaceutical Company Inc. Method of treatment of a metabolic disease using intranasal administration of exendin peptide
WO2006083254A1 (en) 2004-02-11 2006-08-10 Amylin Pharmaceuticals, Inc. Amylin family peptides and methods for making and using them
US8603969B2 (en) 2004-02-11 2013-12-10 Amylin Pharmaceuticals, Llc Pancreatic polypeptide family motifs and polypeptides comprising the same
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
EP2417980A1 (en) 2004-02-11 2012-02-15 Amylin Pharmaceuticals Inc. Hybrid polypeptides with selectable properties
US7399744B2 (en) 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
US20060110423A1 (en) 2004-04-15 2006-05-25 Wright Steven G Polymer-based sustained release device
EA200601904A1 (ru) 2004-04-15 2007-02-27 Алкермес, Инк. Система отсроченного высвобождения лекарственного средства на основе полимеров
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
WO2005117584A2 (en) 2004-05-28 2005-12-15 Amylin Pharmaceuticals, Inc Improved transmucosal delivery of peptides and proteins
US20090069226A1 (en) 2004-05-28 2009-03-12 Amylin Pharmaceuticals, Inc. Transmucosal delivery of peptides and proteins
US8410047B2 (en) 2004-06-11 2013-04-02 Novo Nordisk A/S Counteracting drug-induced obesity using GLP-1 agonists
US7534763B2 (en) * 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
CN101027318B (zh) 2004-07-19 2016-05-25 比奥孔有限公司 胰岛素-低聚物共轭物，制剂及其用途
BRPI0512396A (pt) 2004-07-21 2008-03-11 Ambrx Inc polipeptìdeos biossintéticos utilizando aminoácidos codificados não naturalmente
CA2575756A1 (en) 2004-08-03 2006-02-16 Biorexis Technology, Inc. Combination therapy using transferrin fusion proteins comprising glp-1
JP4965446B2 (ja) 2004-08-31 2012-07-04 ノヴォ ノルディスク アー／エス ペプチド、ポリペプチド及びタンパク質の安定化のためのトリス（ヒドロキシメチル）アミノメタンの使用
DE102004043153B4 (de) 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
EP1791554A2 (en) 2004-09-17 2007-06-06 Novo Nordisk A/S Pharmaceutical compositions containing insulin and insulinotropic peptide
NZ554426A (en) 2004-10-01 2010-05-28 Ramscor Inc Conveniently implantable sustained release drug compositions comprising at least one non-polymeric excipient
US8030273B2 (en) 2004-10-07 2011-10-04 Novo Nordisk A/S Protracted exendin-4 compounds
US7595294B2 (en) 2004-10-08 2009-09-29 Transition Therapeutics, Inc. Vasoactive intestinal polypeptide pharmaceuticals
WO2006044531A2 (en) 2004-10-13 2006-04-27 Isis Parmaceuticals, Inc. Antisense modulation of ptp1b expression
US7442682B2 (en) 2004-10-19 2008-10-28 Nitto Denko Corporation Transepithelial delivery of peptides with incretin hormone activities
BRPI0517341A (pt) 2004-11-12 2008-10-07 Novo Nordisk As composição farmacêutica estável em prateleira, métodos para a preparação de uma composição farmacêutica, para o tratamento de hiperglicemia, para o tratamento de obesidade, deficiência de célula beta, igt ou dislipidemia, para a preparação de uma solução estável de um composto glp-1, para a preparação de um composto glp-1 estável e para a preparação de uma composição farmacêutica estável em prateleira de um composto glp-1, solução estável de um composto glp-1, e, uso de uma solução estável de um composto glp-1
CN101056650A (zh) 2004-11-12 2007-10-17 诺和诺德公司 促胰岛素肽的稳定制剂
WO2006051103A2 (en) 2004-11-12 2006-05-18 Novo Nordisk A/S Stable formulations of peptides
CN101128487B (zh) 2004-12-02 2012-10-10 杜门蒂斯有限公司 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体
CA2836267C (en) 2004-12-13 2016-06-21 Amylin Pharmaceuticals, Llc Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
US7851565B2 (en) 2004-12-21 2010-12-14 Nektar Therapeutics Stabilized polymeric thiol reagents
PL1831252T3 (pl) 2004-12-22 2009-11-30 Lilly Co Eli Preparaty białka fuzyjnego analogu GLP-1
US20070021336A1 (en) 2004-12-24 2007-01-25 Christen Anderson Use of GLP-1 and agonists thereof to prevent cardiac myocyte apoptosis
JP4785206B2 (ja) 2005-01-14 2011-10-05 ウクスィ・グランドチャンプ・ファーマシューティカル・テクノロジー・カンパニー・リミテッド 修飾されたエキセンディン（Ｅｘｅｎｄｉｎｓ）及びその使用
US8716221B2 (en) 2005-01-14 2014-05-06 Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. Modified exendins and uses thereof
WO2006082588A2 (en) 2005-02-07 2006-08-10 Pharmalight Inc. Method and device for ophthalmic administration of active pharmaceutical ingredients
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
BRPI0606992A2 (pt) 2005-02-11 2009-07-28 Amylin Pharmaceuticals Inc análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
WO2006097535A2 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Peptide agonists of the glucagon family with secretin like activity
WO2006110887A2 (en) 2005-04-11 2006-10-19 Amylin Pharmaceuticals, Inc Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling
CN101163514B (zh) 2005-04-24 2012-01-25 诺和诺德公司 注射装置
JP5235661B2 (ja) 2005-05-25 2013-07-10 ノボ・ノルデイスク・エー／エス 安定化ポリペプチド製剤
CA2609810C (en) 2005-06-06 2012-05-22 Camurus Ab Glp-1 analogue formulations
JP2008543816A (ja) 2005-06-13 2008-12-04 インペリアル イノベーションズ リミテッド 新規化合物および該化合物が摂食行動に及ぼす効果
GB0511986D0 (en) 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
RS53968B1 (sr) 2005-06-16 2015-08-31 Nektar Therapeutics Konjugati koji imaju spojnicu koja može da se razgradi i polimerni reagensi koji su korisni za pripremu takvih konjugata
JP2009503111A (ja) 2005-08-04 2009-01-29 ネクター セラピューティックス エイエル，コーポレイション Ｇ−ｃｓｆ部分および重合体の複合体
CA2658678A1 (en) 2005-08-06 2007-02-15 Gerald J. Prud'homme Composition and method for prevention and treatment of type i diabetes
EP2330124B1 (en) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
LT2347762T (lt) 2005-08-19 2019-08-26 Amylin Pharmaceuticals, Llc Eksendinas, skirtas diabeto gydymui ir kūno svorio mažinimui
KR101486397B1 (ko) 2005-09-14 2015-01-28 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
JP5072848B2 (ja) 2005-09-20 2012-11-14 ノバルティス アーゲー 低血糖イベントを低減するためのｄｐｐ−ｉｖ阻害剤の使用
US8759290B2 (en) 2005-10-18 2014-06-24 Biocon Limited Oral glucagon-like peptide conjugates for metabolic diseases
US7687608B2 (en) 2005-10-19 2010-03-30 Smartcells, Inc. Methods for reducing the mitogenicity of lectin compositions
CA2913805A1 (en) 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
EP1968607B1 (en) 2005-12-02 2014-01-15 Nabil Habib Lab Treatment of cancer and other diseases
MX2008007075A (es) 2005-12-02 2008-11-12 Mdrna Inc Formulacion farmaceutica para incrementar la permeabilidad epitelial por peptido regulador de glucosa.
WO2007067964A2 (en) 2005-12-08 2007-06-14 Nastech Pharmaceutical Company Inc. Mucosal delivery of stabilized formulations of exendin
WO2007075534A2 (en) 2005-12-16 2007-07-05 Nektar Therapeutics Al, Corporation Polymer conjugates of glp-1
ES2779992T3 (es) 2005-12-20 2020-08-21 Univ Duke Métodos y composiciones para suministrar agentes activos con propiedades farmacológicas potenciadas
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
SI1984009T1 (sl) 2006-01-18 2013-02-28 Qps, Llc Farmacevtski sestavki z izboljĺ ano stabilnostjo
KR20080098504A (ko) 2006-02-03 2008-11-10 메디뮨 엘엘씨 단백질 제제
US7704953B2 (en) 2006-02-17 2010-04-27 Mdrna, Inc. Phage displayed cell binding peptides
CN101432025B (zh) 2006-03-21 2012-04-04 安米林药品公司 肽-肽酶抑制剂结合物及其使用方法
NZ571862A (en) 2006-04-13 2011-10-28 Ipsen Pharma Sas Pharmaceutical composition comprising HGLP-1, a zinc divalent metal ion and a solvent
RU2409349C2 (ru) 2006-04-14 2011-01-20 Маннкайнд Корпорейшн Фармацевтические композиции, содержащие глюкагонподобный пептид(glp-1)
DE202006006388U1 (de) 2006-04-20 2007-08-30 Tegometall (International) Ag Regal-Fachboden
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2029160A2 (en) 2006-05-12 2009-03-04 Amylin Pharmaceuticals, Inc. Methods to restore glycemic control
CN101454342A (zh) 2006-05-26 2009-06-10 安米林药品公司 用于治疗充血性心力衰竭的组合物及方法
EP2021014A1 (en) * 2006-05-26 2009-02-11 Brystol-Myers Squibb Company Sustained release glp-1 receptor modulators
ES2401856T3 (es) 2006-06-21 2013-04-25 Biocon Limited Un método para producir un polipéptido biológicamente activo que tiene actividad insulinotrópica
EP2051697A2 (en) 2006-07-05 2009-04-29 Foamix Ltd. Foamable vehicle comprising dicarboxylic acid or dicarboxylic acid ester and pharmaceutical compositions thereof
CN101511868B (zh) 2006-07-24 2013-03-06 比奥雷克西斯制药公司 毒蜥外泌肽融合蛋白
US7928186B2 (en) 2006-08-02 2011-04-19 Phoenix Pharmaceuticals, Inc. Cell permeable bioactive peptide conjugates
AU2007281433A1 (en) 2006-08-04 2008-02-07 Nastech Pharmaceutical Company Inc. Compositions for intranasal delivery of human insulin and uses thereof
JP5048773B2 (ja) 2006-08-09 2012-10-17 インターシア セラピューティクス，インコーポレイティド 浸透圧式デリバリーシステム及びピストンアセンブリー
AU2007284365A1 (en) 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. DPP-IV resistant GIP hybrid polypeptides with selectable properties
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
US20090318353A1 (en) 2006-08-25 2009-12-24 Novo Nordisk A/S Acylated Exendin-4 Compounds
CN101125207B (zh) 2006-11-14 2012-09-05 上海华谊生物技术有限公司 带有聚乙二醇基团的艾塞丁或其类似物及其制剂和用途
JP2010512399A (ja) 2006-12-12 2010-04-22 アミリン・ファーマシューティカルズ，インコーポレイテッド 医薬製剤及びその調製方法
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
RU2432361C2 (ru) 2007-01-05 2011-10-27 КовЭкс Текнолоджиз Айэлэнд Лимитед Соединения агонисты рецептора глюкагоноподобного белка-1 (glp-1r)
WO2008086086A2 (en) 2007-01-05 2008-07-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
CN101663317A (zh) 2007-01-05 2010-03-03 CovX科技爱尔兰有限公司 胰高血糖素样蛋白-1受体glp-1r激动剂化合物
WO2008098212A2 (en) 2007-02-08 2008-08-14 Diobex, Inc. Extended release formulations of glucagon and other peptides and proteins
MX2009008241A (es) 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Co-agonistas de receptor de glucagon/glp-1.
WO2008130066A1 (en) 2007-04-20 2008-10-30 Kang Choon Lee Mono modified exendin with polyethylene glycol or its derivatives and uses thereof
NZ580447A (en) 2007-04-23 2011-06-30 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and uses thereof
US8236760B2 (en) 2007-04-27 2012-08-07 Cedars-Sinsai Medical Center Use of GLP-1 receptor agonists for the treatment of short bowel syndrome
US7829664B2 (en) 2007-06-01 2010-11-09 Boehringer Ingelheim International Gmbh Modified nucleotide sequence encoding glucagon-like peptide-1 (GLP-1), nucleic acid construct comprising same for production of glucagon-like peptide-1 (GLP-1), human cells comprising said construct and insulin-producing constructs, and methods of use thereof
US9353170B2 (en) 2007-06-08 2016-05-31 Sanofi-Aventis Deutschland Gmbh Long-acting transient polymer conjugates of exendin
EP2158214B1 (en) 2007-06-15 2011-08-17 Zealand Pharma A/S Glucagon analogues
EP2175834B8 (en) 2007-07-10 2012-08-22 Eli Lilly And Company Glp-1-fc fusion protein formulation
CA2693504A1 (en) 2007-08-03 2009-02-12 Eli Lilly And Company Treatment for obesity
CN101366692A (zh) 2007-08-15 2009-02-18 江苏豪森药业股份有限公司 一种稳定的艾塞那肽制剂
MX2010002264A (es) 2007-08-30 2010-08-02 Curedm Inc Composiciones y métodos para utilizar péptidos proislet y sus analogos.
US20100261637A1 (en) 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
US20100256056A1 (en) 2007-09-07 2010-10-07 Zheng Xin Dong Analogues of exendin-4 and exendin-3
JP5813323B2 (ja) 2007-10-24 2015-11-17 マンカインド コーポレイション 活性薬剤の送達方法
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
KR101736502B1 (ko) 2007-10-24 2017-05-16 맨카인드 코포레이션 Ｇｌｐ-1에 의한 유해 효과의 예방 방법
ES2558155T3 (es) 2007-10-30 2016-02-02 Indiana University Research And Technology Corporation Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1
US8981047B2 (en) 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Glucagon antagonists
DK2597103T3 (en) 2007-11-16 2017-02-13 Novo Nordisk As Stable pharmaceutical compositions comprising liraglutide and degludec
WO2009067268A1 (en) 2007-11-23 2009-05-28 Michael Rothkopf Methods of enhancing diabetes resolution
CN101444618B (zh) 2007-11-26 2012-06-13 杭州九源基因工程有限公司 含有艾塞那肽的药物制剂
CN102026666B (zh) 2007-12-11 2013-10-16 常山凯捷健生物药物研发（河北）有限公司 促胰岛素肽缀合物制剂
CN101983066B (zh) 2008-01-30 2016-06-29 印第安那大学科技研究公司 基于酯的胰岛素前药
RS58948B1 (sr) 2008-02-01 2019-08-30 Ascendis Pharma As Prolek koji sadrži linker koji se može sam odcepiti
MX2010008654A (es) 2008-02-06 2010-10-06 Biocon Ltd Medios de fermentacion y procedimientos para los mismos.
WO2009114959A1 (zh) 2008-03-20 2009-09-24 中国人民解放军军事医学科学院毒物药物研究所 可注射用缓释药物制剂及其制备方法
EP2282763B1 (en) 2008-04-07 2013-12-11 National Institute Of Immunology Process for preparing supramolecular calcitonin assemblies (SCA)
KR20110007614A (ko) 2008-05-07 2011-01-24 메리온 리서치 Ⅲ 리미티드 ＧｎＲＨ 관련 화합물의 조성물 및 제조 방법
US20110263496A1 (en) 2008-05-21 2011-10-27 Amylin Pharmaceuticals, Inc. Exendins to lower cholesterol and triglycerides
EP2288918A1 (en) 2008-05-23 2011-03-02 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonist bioassays
US9358352B2 (en) 2008-06-13 2016-06-07 Mannkind Corporation Dry powder drug delivery system and methods
RU2608439C2 (ru) 2008-06-13 2017-01-18 Маннкайнд Корпорейшн Ингалятор для сухого порошка и система для доставки лекарственных средств
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
BRPI0915282A2 (pt) 2008-06-17 2017-02-07 Univ Indiana Res & Tech Corp agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade
BRPI0914889A2 (pt) 2008-06-17 2015-11-24 Otsuka Chemical Co Ltd peptídeo glp-1 adicionado de cadeia oligossacarídica
KR20110039230A (ko) 2008-06-17 2011-04-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 생리학적 ｐＨ 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체
PA8830501A1 (es) 2008-06-17 2010-07-27 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
CA2726894A1 (en) 2008-06-27 2009-12-30 Duke University Therapeutic agents comprising elastin-like peptides
EP2303247A4 (en) 2008-07-21 2012-08-01 Syneron Medical Ltd TRANSDERMALES SYSTEM FOR THE EXTENDED RELEASE OF INCRETINS AND INCRETIN MIMETIC PEPTIDES
WO2010013012A2 (en) 2008-08-01 2010-02-04 Lund University Bioscience Ab Novel polypeptides and uses thereof
CN101670096B (zh) 2008-09-11 2013-01-16 杭州九源基因工程有限公司 含有艾塞那肽的药物制剂
CN103736082A (zh) 2008-10-17 2014-04-23 赛诺菲-安万特德国有限公司 胰岛素和glp-1激动剂的组合
WO2010068735A1 (en) 2008-12-10 2010-06-17 Glaxosmithkline Llc. Pharmaceutical compositions
US8642541B2 (en) 2008-12-15 2014-02-04 Zealand Pharma A/S Glucagon analogues
EA020596B1 (ru) 2008-12-15 2014-12-30 Зилэнд Фарма А/С Аналоги глюкагона
AU2008365556A1 (en) 2008-12-15 2011-07-21 Zealand Pharma A/S Glucagon analogues
US8685919B2 (en) 2008-12-15 2014-04-01 Zealand Pharma A/S Glucagon analogues
SG172291A1 (en) 2008-12-19 2011-07-28 Univ Indiana Res & Tech Corp Amide based glucagon superfamily peptide prodrugs
CN101538323B (zh) 2009-01-13 2012-05-09 深圳翰宇药业股份有限公司 一种纯化艾塞那肽的方法
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
EP2403490B1 (en) 2009-03-04 2019-08-07 MannKind Corporation An improved dry powder drug delivery system
CA2753939A1 (en) 2009-03-05 2010-09-10 Sanofi-Aventis Deutschland Gmbh Drug delivery device with retractable needle
EP2413955A4 (en) 2009-04-01 2012-12-26 Amylin Pharmaceuticals Inc N-TERMINAL CONFORMATION RESTRICTED GLP-1 RECEPTOR AGONIST COMPOUNDS
WO2010118034A2 (en) 2009-04-06 2010-10-14 Board Of Regents, The University Of Texas System Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells
CA2758445C (en) 2009-04-22 2016-02-16 Alteogen, Inc. In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasing in vivo half-life using same
CN101870728A (zh) 2009-04-23 2010-10-27 派格生物医药(苏州)有限公司 新型Exendin变体及其缀合物
CN101559041B (zh) 2009-05-19 2014-01-15 中国科学院过程工程研究所 粒径均一的多肽药物缓释微球或微囊制剂及制备方法
CA2760760A1 (en) 2009-05-20 2010-11-25 Sanofi-Aventis Deutschland Gmbh A bung for drug containing cartridges in drug delivery devices
EP3189868B1 (en) 2009-05-20 2024-10-23 Sanofi-Aventis Deutschland GmbH A bung for drug containing cartridges in drug delivery devices comprising an electronic coding feature
US20120231022A1 (en) 2009-05-28 2012-09-13 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonist compounds for sleep enhancement
EP2440235A1 (en) 2009-06-11 2012-04-18 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
PE20120914A1 (es) 2009-06-16 2012-08-22 Univ Indiana Res & Tech Corp Compuestos glucagon activo de receptor de gip
JP5932642B2 (ja) 2009-07-02 2016-06-08 アンジオケム インコーポレーテッド 多量体ペプチドコンジュゲートおよびその使用
DK2454282T3 (en) 2009-07-13 2015-05-04 Zealand Pharma As acetylated glucagonanaloger
CN101601646B (zh) 2009-07-22 2011-03-23 南京凯瑞尔纳米生物技术有限公司 治疗糖尿病的鼻腔滴剂及其制备方法
WO2011011675A1 (en) 2009-07-23 2011-01-27 Zelos Therapeutics, Inc. Pharmaceutically acceptable formulations/compositions for peptidyl drugs
EP2459228B1 (en) 2009-07-31 2020-03-04 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an insulin linker conjugate
WO2011017835A1 (en) 2009-08-11 2011-02-17 Nanjing University Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
US20120148586A1 (en) 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
KR20120092611A (ko) 2009-09-30 2012-08-21 글락소 그룹 리미티드 연장된 반감기를 갖는 약물 융합체 및 컨쥬게이트
US20110097386A1 (en) 2009-10-22 2011-04-28 Biodel, Inc. Stabilized glucagon solutions
US9610329B2 (en) 2009-10-22 2017-04-04 Albireo Pharma, Inc. Stabilized glucagon solutions
DK2490708T3 (da) 2009-10-22 2013-04-15 Biodel Inc Stabiliserede glucagon-opløsninger
AU2010312655A1 (en) 2009-10-30 2012-05-03 Glytech, Inc. Glycosylated form of antigenic GLP-1 analogue
US20120294855A1 (en) 2009-11-03 2012-11-22 Eli Lilly & Company Glp-1 receptor agonist compounds for obstructive sleep apnea
AU2010317995B2 (en) 2009-11-13 2014-04-17 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
CN102711804B (zh) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 包含glp-1激动剂和甲硫氨酸的药物组合物
KR20120092714A (ko) 2009-12-15 2012-08-21 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 비만 및 다른 대사성 질환의 치료를 위한 ｐｐａｒ 절약형 티아졸리딘디온 및 복합제
AU2010340058A1 (en) 2009-12-15 2012-06-21 Metabolic Solutions Development Company, Llc PPAR-sparing thiazolidinediones and combinations for the treatment of diabetes mellitus and other metabolic diseases
DK2513070T3 (en) 2009-12-15 2018-01-22 Cirius Therapeutics Inc PPAR-sparing thiazolidinedione salts for the treatment of metabolic disorders
EP2512470B1 (en) 2009-12-15 2016-11-30 Octeta Therapeutics, LLC Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
JP6006118B2 (ja) 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
WO2011075623A1 (en) 2009-12-18 2011-06-23 Latitude Pharmaceuticals, Inc. One - phase gel compos ition compri s ing phos pholi pids
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
CN101798588B (zh) 2009-12-21 2015-09-09 上海仁会生物制药股份有限公司 Glp-1受体激动剂生物学活性测定方法
JO2976B1 (en) 2009-12-22 2016-03-15 ايلي ليلي اند كومباني Axentomodulin polypeptide
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
MX342409B (es) 2010-01-20 2016-09-28 Zealand Pharma As Tratamiento de enfermedades cardiacas.
RU2012136450A (ru) 2010-01-27 2014-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения
AU2011209472B2 (en) 2010-02-01 2014-07-24 Sanofi-Aventis Deutschland Gmbh Cartridge holder, drug delivery device and method for securing a cartridge in a cartridge holder
WO2011109784A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Formulation of insulinotropic peptide conjugates
CN102918055B (zh) 2010-03-26 2017-03-29 诺沃—诺迪斯克有限公司 新的胰高血糖素类似物
AR080592A1 (es) 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
EP2568993A4 (en) 2010-05-13 2014-02-19 Univ Indiana Res & Tech Corp GLUCAGON SUPERFAMILY PEPTIDES WITH G-PROTEIN-COUPLED RECEPTOR ACTIVITY
CN103079587B (zh) 2010-05-13 2016-05-11 印第安纳大学研究及科技有限公司 呈现核激素受体活性的胰高血糖素超家族肽
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
JP2013529080A (ja) 2010-05-20 2013-07-18 グラクソ グループ リミテッド 改良された抗血清アルブミン結合変異体
US8263554B2 (en) 2010-06-09 2012-09-11 Amylin Pharmaceuticals, Inc. Methods of using GLP-1 receptor agonists to treat pancreatitis
CN101891823B (zh) 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 一种Exendin-4及其类似物融合蛋白
US8636711B2 (en) 2010-06-14 2014-01-28 Legacy Emanuel Hospital & Health Center Stabilized glucagon solutions and uses therefor
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
US9234023B2 (en) 2010-06-24 2016-01-12 Biousian Biosystems, Inc. Glucagon-like peptide-1 glycopeptides
WO2011163012A2 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
US20120046225A1 (en) 2010-07-19 2012-02-23 The Regents Of The University Of Colorado, A Body Corporate Stable glucagon formulations for the treatment of hypoglycemia
WO2012012352A2 (en) 2010-07-19 2012-01-26 Amidebio, Llc Modified peptides and proteins
EA201390182A1 (ru) 2010-07-28 2014-01-30 АМИЛИН ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Соединения-агонисты рецептора glp-1, содержащие стабилизированные области
CN102397558B (zh) 2010-09-09 2013-08-14 中国人民解放军军事医学科学院毒物药物研究所 Exendin-4类似物的定位聚乙二醇化修饰物及其用途
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
EP3028720A1 (en) 2010-09-28 2016-06-08 Amylin Pharmaceuticals, LLC Engineered polypeptides having enhanced duration of action
ES2533601T3 (es) 2010-11-03 2015-04-13 Arecor Limited Nueva composición que comprende glucagón
CN103200940A (zh) 2010-11-09 2013-07-10 曼金德公司 用于治疗偏头痛的包含血清素受体激动剂和二酮哌嗪的组合物
EP2460552A1 (en) 2010-12-06 2012-06-06 Sanofi-Aventis Deutschland GmbH Drug delivery device with locking arrangement for dose button
RS60321B1 (sr) 2010-12-16 2020-07-31 Novo Nordisk As Čvrste kompozicije koje sadrže glp-1 agonist i so n-(8-(2- hidroksibenzoil)amino)kaprilne kiseline
KR20130132931A (ko) 2010-12-22 2013-12-05 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Gip 수용체 활성을 나타내는 글루카곤 유사체들
JP2014504588A (ja) 2010-12-22 2014-02-24 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 膵島細胞移植のためのｇｌｐ−１受容体アゴニスト
CN102532301B (zh) 2010-12-31 2014-09-03 上海医药工业研究院 一类新型的Exendin-4类似物及其制备方法
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN102100906A (zh) 2011-02-18 2011-06-22 深圳翰宇药业股份有限公司 一种艾塞那肽的药用制剂及其制备方法
EP2683364B1 (en) 2011-03-10 2017-01-18 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
CN102718858B (zh) 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
CN106928341B (zh) 2011-03-30 2021-06-01 上海仁会生物制药股份有限公司 定点单取代聚乙二醇化Exendin类似物及其制备方法
EP2694095B1 (en) 2011-04-05 2018-03-07 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
US9480751B2 (en) 2011-04-11 2016-11-01 Yeda Research And Development Co. Ltd. Albumin binding probes and drug conjugates thereof
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
CN102766204B (zh) 2011-05-05 2014-10-15 天津药物研究院 胰高血糖素样肽-1突变体多肽及其制备方法和其应用
AU2012255119B2 (en) 2011-05-18 2017-04-20 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
JP2014521594A (ja) 2011-05-25 2014-08-28 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 長持続期間デュアルホルモンコンジュゲート
DE102011102879B4 (de) 2011-05-31 2014-03-27 Pewag Schneeketten Gmbh & Co Kg Kettenglied für Gleitschutzketten für Fahrzeugreifen, sowie Gleitschutzkette umfassend solche Kettenglieder
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
DK3878859T5 (da) 2011-06-10 2024-06-10 Hanmi Science Co Ltd Hidtil ukendte oxyntomodulinderivater og farmaceutisk præparat til behandling af fedme omfattende disse
KR102002783B1 (ko) 2011-06-10 2019-07-24 베이징 한미 파마슈티컬 컴퍼니 리미티드 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용
SI2721062T1 (sl) 2011-06-17 2019-03-29 Hanmi Science Co., Ltd. Konjugat, obsegajoč oksintomodulinski in imunoglobinski fragment, in uporaba le-tega
JP6184404B2 (ja) 2011-06-22 2017-08-23 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション グルカゴン／ｇｌｐ−１レセプターコアゴニスト
KR101972617B1 (ko) 2011-06-22 2019-04-25 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/glp-1 수용체 공동-항진제들
EP2723359A4 (en) 2011-06-24 2015-03-11 Amylin Pharmaceuticals Llc METHOD FOR THE TREATMENT OF DIABETES WITH THE HELP OF DELAYED RELEASED FORMULATIONS FROM GLP-1 RECEPTOR AGONISTS
KR101357117B1 (ko) 2011-06-28 2014-02-06 비앤엘델리팜 주식회사 폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
WO2013004983A1 (en) 2011-07-04 2013-01-10 Imperial Innovations Limited Novel compounds and their effects on feeding behaviour
EP2729481B1 (en) 2011-07-08 2018-10-17 Amylin Pharmaceuticals, LLC Engineered polypeptides having enhanced duration of action with reduced immunogenicity
DK2741765T3 (en) 2011-08-10 2016-06-13 Adocia Injectable solution of at least one type of basal insulin
EP4295858A1 (en) 2011-08-24 2023-12-27 ImmunoForge Co., Ltd. Formulations of active agents for sustained release
CN103189389B (zh) 2011-09-03 2017-08-11 深圳市健元医药科技有限公司 新的glp‑ⅰ类似物及其制备方法和用途
AR088161A1 (es) 2011-09-23 2014-05-14 Novo Nordisk As Analogos de glucagon
BR112014010200A2 (pt) 2011-10-28 2020-10-27 Sanofi-Aventis Deutschland Gmbh combinação farmacêutica, bem como seu uso na preparação de um medicamento para o tratamento de diabetes tipo 2
CN102363633B (zh) 2011-11-16 2013-11-20 天津拓飞生物科技有限公司 胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用
BR112014007124A2 (pt) 2011-11-17 2017-06-13 Univ Indiana Res & Tech Corp superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide
CN103998046B (zh) 2011-11-29 2021-04-06 优奥斯私人有限公司 包含环糊精和疏水性药物的可注射药物组合物的防腐方法
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
AU2012356219B2 (en) 2011-12-22 2016-03-31 Covx Technologies Ireland Limited Anti-diabetic compounds
SG11201403377QA (en) 2011-12-23 2014-07-30 Zealand Pharma As Glucagon analogues
EP2797585A4 (en) 2011-12-29 2015-10-07 Latitude Pharmaceuticals Inc STABILIZED GLUCAGONNANOULULSIONS
BR112014016889A8 (pt) 2012-01-09 2017-07-04 Adocia composição sob a forma de uma solução aquosa injetável, sujo ph está compreendido entre 6,0 e 8,0 e, formulação de dose unitária com ph compreendido entre 7 e 7,8
WO2013148966A1 (en) 2012-03-28 2013-10-03 Amylin Pharmaceuticals, Llc Transmucosal delivery of engineered polypeptides
WO2013148871A1 (en) 2012-03-28 2013-10-03 Amylin Pharmaceuticals, Llc Engineered polypeptides
JP2015516143A (ja) 2012-04-02 2015-06-08 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド
WO2013151666A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of biologics and proteins associated with human disease
EP2841090A1 (en) 2012-04-24 2015-03-04 Amylin Pharmaceuticals, LLC Site-specific enzymatic modification of exendins and analogs thereof
US20130289241A1 (en) 2012-04-26 2013-10-31 Shanghai Ambiopharm, Inc. Method for preparing exenatide
US8901484B2 (en) 2012-04-27 2014-12-02 Sanofi-Aventis Deutschland Gmbh Quantification of impurities for release testing of peptide products
WO2013182217A1 (en) 2012-04-27 2013-12-12 Sanofi-Aventis Deutschland Gmbh Quantification of impurities for release testing of peptide products
EP2844670B1 (en) 2012-05-03 2017-12-06 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues
EP2664374A1 (en) 2012-05-15 2013-11-20 F. Hoffmann-La Roche AG Lysin-glutamic acid dipeptide derivatives
CN103421094A (zh) 2012-05-24 2013-12-04 上海医药工业研究院 一种具有epo类似活性的多肽化合物
EP2855627B1 (en) 2012-05-25 2017-09-20 Merck Patent GmbH Bimesogenic compounds and mesogenic media
US20150174209A1 (en) 2012-05-25 2015-06-25 Amylin Pharmaceuticals. Llc Insulin-pramlintide compositions and methods for making and using them
SG11201407860PA (en) 2012-06-14 2014-12-30 Sanofi Sa Exendin-4 peptide analogues
CA2877127A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Analogs of glucagon exhibiting gip receptor activity
CA2878457C (en) 2012-07-12 2021-01-19 Mannkind Corporation Dry powder drug delivery systems and methods
CA2878991C (en) 2012-07-23 2021-12-07 Zealand Pharma A/S Glucagon analogues
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
AR092862A1 (es) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
WO2014027253A1 (en) 2012-08-14 2014-02-20 Wockhardt Limited Pharmaceutical microparticulate compositions of polypeptides
US20150258198A1 (en) 2012-08-14 2015-09-17 Wockhardt Limited Pharmaceutical microparticulate compositions of polypeptides
CN102816244A (zh) 2012-08-23 2012-12-12 无锡和邦生物科技有限公司 一种Exendin-4肽与人血清白蛋白HSA的融合蛋白及其制备方法
CN102827270A (zh) 2012-09-13 2012-12-19 无锡和邦生物科技有限公司 一种聚乙二醇化艾塞那肽衍生物及其用途
US9546205B2 (en) 2012-09-17 2017-01-17 Imperial Innovations Limited Peptide analogues of glucagon and GLP1
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
MY168536A (en) 2012-11-06 2018-11-12 Hanmi Pharm Ind Co Ltd Liquid formulation of protein conjugate comprising an oxyntomodulin derivative covalently linked to a non-peptidyl polymer to an immunoglobulin fc region
AU2013347975B2 (en) 2012-11-20 2018-07-26 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
TWI674270B (zh) 2012-12-11 2019-10-11 英商梅迪繆思有限公司 用於治療肥胖之升糖素與glp-1共促效劑
MX2015008114A (es) 2012-12-21 2015-11-06 Sanofi Sa Derivados de exendina-4.
CN103908657A (zh) 2012-12-31 2014-07-09 复旦大学附属华山医院 胰升糖素样肽-1类似物在制备眼科疾病药物中的用途
WO2014158900A1 (en) 2013-03-14 2014-10-02 Indiana University Research And Technology Corporation Insulin-incretin conjugates
EP3238734A1 (en) 2013-03-14 2017-11-01 Medimmune Limited Pegylated glucagon and glp-1 co-agonists for the treatment of obesity
US20160058881A1 (en) 2013-03-15 2016-03-03 Indiana University Research And Technology Corporation Prodrugs with prolonged action
SI2986313T1 (sl) 2013-04-18 2019-09-30 Novo Nordisk A/S Stabilni koagonisti GLP-1 / glukagonskega receptorja z dolgotrajnim učinkom za medicinsko uporabo
JP2014227368A (ja) 2013-05-21 2014-12-08 国立大学法人帯広畜産大学 糖尿病および高血糖状態の処置のためのグルカゴンアナログ
CN103304660B (zh) 2013-07-12 2016-08-10 上海昂博生物技术有限公司 一种利拉鲁肽的合成方法
CN103405753B (zh) 2013-08-13 2016-05-11 上海仁会生物制药股份有限公司 稳定的促胰岛素分泌肽水针药物组合物
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
PT3057984T (pt) 2013-10-17 2018-10-24 Boehringer Ingelheim Int Análogos de glucagon acilados
JP2017503474A (ja) 2013-11-06 2017-02-02 ジーランド ファーマ アクティーゼルスカブ グルカゴン−ｇｌｐ−１−ｇｉｐトリプルアゴニスト化合物
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
EP3080155A1 (en) 2013-12-13 2016-10-19 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
EP3080151A1 (en) 2013-12-13 2016-10-19 Sanofi Exendin-4 peptide analogues
CN103665148B (zh) 2013-12-17 2016-05-11 中国药科大学 一种可口服给药的降糖多肽及其制法和用途
CN103980358B (zh) 2014-01-03 2016-08-31 杭州阿诺生物医药科技股份有限公司 一种制备利拉鲁肽的方法
KR20160104726A (ko) 2014-01-09 2016-09-05 사노피 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 무글리세롤 약제학적 제형
RU2016132342A (ru) 2014-01-09 2018-02-14 Санофи Стабилизированные фармацевтические составы на основе инсулиновых аналогов и/или инсулиновых производных
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN106519015B (zh) 2014-09-23 2020-04-17 深圳市图微安创科技开发有限公司 胃泌酸调节素类似物
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物

Also Published As

Publication number Publication date
LT3157949T (lt) 2018-11-12
PT3157949T (pt) 2018-11-09
HUE039702T2 (hu) 2019-01-28
WO2015193381A1 (en) 2015-12-23
ES2691534T3 (es) 2018-11-27
EP3157949B1 (en) 2018-07-18
BR112016029582A2 (pt) 2017-10-31
JP6581606B2 (ja) 2019-09-25
CA2951077A1 (en) 2015-12-23
PL3157949T3 (pl) 2018-12-31
CN106715466A (zh) 2017-05-24
TW201613633A (en) 2016-04-16
US20150368311A1 (en) 2015-12-24
SI3157949T1 (sl) 2018-11-30
IL249583A0 (en) 2017-02-28
DK3157949T3 (en) 2018-11-12
CY1121032T1 (el) 2019-12-11
AU2015276203B2 (en) 2019-01-31
JP2017523147A (ja) 2017-08-17
CN106715466B (zh) 2020-09-15
HRP20181708T1 (hr) 2018-12-28
EP3157949A1 (en) 2017-04-26
US9932381B2 (en) 2018-04-03
TR201815158T4 (tr) 2018-11-21
UY36179A (es) 2016-01-29
RU2017101377A (ru) 2018-07-19
SG11201609478PA (en) 2016-12-29
AR100888A1 (es) 2016-11-09
MX367348B (es) 2019-08-15
RU2017101377A3 (es) 2019-02-06
KR20170018433A (ko) 2017-02-17
AU2015276203A1 (en) 2016-12-15

Similar Documents

Publication Publication Date Title
MX367348B (es) Derivados de exendina-4 como agonistas selectivos del receptor de glucagon.
PH12020551742A1 (en) Gip derivatives and uses thereof
MX2015000990A (es) Analogos del glucagon.
EP3922260A3 (en) Insulin receptor partial agonists and glp-1 analogues
PE20210162A1 (es) Analogos de incretina y sus usos
CY1120862T1 (el) Παραγοντες επαγωγης αποπτωσης για τη θεραπευτικη αγωγη καρκινου και ανοσων και αυτοανοσων ασθενειων
CY1121348T1 (el) Mrna θεραπεια για την θεραπευτικη αγωγη οφθαλμικων ασθενειων
MY187047A (en) Selective pyy compounds and uses thereof
CL2017003185A1 (es) Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1)
EA201790371A1 (ru) Модифицированные варианты il-2, которые селективно активируют регуляторные т-клетки, для лечения аутоиммунных заболеваний
MX2016013243A (es) Agonistas peptídicos duales de los receptores de glp-1/glucagón derivados de la exendina-4.
CL2016003075A1 (es) Composición para tratar diabetes, que contiene un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada
MX376200B (es) Formulacion en polvo nasal para el tratamiento de hipoglicemia.
CL2017001181A1 (es) Amidas de morfolina y 1,4-oxazepano como agonistas del receptor de somatostatina subtipo 4(sstr4)
MX2016013244A (es) Derivados de exendina-4 como agonistas peptidicos duales del receptor de glp-1/glucagon.
MX2017009595A (es) Compuestos antisenescentes y usos de los mismos.
BR112016016578A2 (pt) Insulina de ação prolongada e uso daanálogo de insulina, polinucleotídeo, vetor de expressão, transformante, insulina de ação prolongada bem como seu método de preparação e formulação da mesma, conjugado, e uso do mesmo mesma
EA201791182A1 (ru) Новые производные 2'- и/или 5'-аминокислотных эфиров фосфороамидатов 3'-дезоксиаденозина в качестве противораковых соединений
MX389178B (es) Formulacion de proporcion fija de insulina glargina/lixisenatida.
MX2023011453A (es) Composiciones para usarse en el tratamiento y prevencion de degeneracion macular.
UY36150A (es) Derivados de naftiridinadiona
EA202091567A1 (ru) Химерные белки мти
EP3530671A3 (en) Gip peptide analogues
EA201690732A1 (ru) Агонисты гуанилатциклазы, используемые для лечения индуцированных опиоидами дисфункций
EA201790482A1 (ru) Модифицированные полипептиды vip3

Legal Events

Date Code Title Description
FG Grant or registration